Liu, Y.; Vorobyeva, A.; Xu, T.; Orlova, A.; Loftenius, A.; Bengtsson, T.; Jonasson, P.; Tolmachev, V.; Frejd, F.Y.
Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics 2021, 13, 839.
https://doi.org/10.3390/pharmaceutics13060839
AMA Style
Liu Y, Vorobyeva A, Xu T, Orlova A, Loftenius A, Bengtsson T, Jonasson P, Tolmachev V, Frejd FY.
Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics. 2021; 13(6):839.
https://doi.org/10.3390/pharmaceutics13060839
Chicago/Turabian Style
Liu, Yongsheng, Anzhelika Vorobyeva, Tianqi Xu, Anna Orlova, Annika Loftenius, Theresa Bengtsson, Per Jonasson, Vladimir Tolmachev, and Fredrik Y. Frejd.
2021. "Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain" Pharmaceutics 13, no. 6: 839.
https://doi.org/10.3390/pharmaceutics13060839
APA Style
Liu, Y., Vorobyeva, A., Xu, T., Orlova, A., Loftenius, A., Bengtsson, T., Jonasson, P., Tolmachev, V., & Frejd, F. Y.
(2021). Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain. Pharmaceutics, 13(6), 839.
https://doi.org/10.3390/pharmaceutics13060839
